Recent news on Flumist

FDA panel says FluMist OK for children under 5 years old  -  May 24, 2007
Business Gazette,MedImmune Inc. won a key ruling last week when a US Food and Drug Administration panel recommended the FDA approve the company’s FluMist nasal vaccine for

FDA Advisory Committee Recommends Expanded Use of FluMist  -  May 18, 2007
SpiritIndia,In addition, the committee voted in favor of the risk-benefit profile of FluMist in children 12 to 59 months of age without a history of wheeze,

FDA committee recommends expanded use of FluMist  -  May 17, 2007
Pharmaceutical Business ReviewMedImmune has revealed that an FDA committee has recommended that use of the company's influenza virus vaccine FluMist be extended to include children under

FDA advisory panel recommends FluMist approval for young children  -  May 17, 2007
CIDRAP,May 17, 2007 (CIDRAP News) – A US Food and Drug Administration (FDA) advisory panel unanimously agreed Wednesday that FluMist, a nasal spray vaccine against

FDA Advisory Committee Recommends Expanded Use of FluMist(R)  -  May 16, 2007
PR Newswire (press release),The committee voted that the data demonstrate the efficacy of FluMist in children 6 to 59 months of age. In addition, the committee voted in favor of the

FDA panel approves FluMist for kids under 5  -  May 17, 2007
The Money Times,An expert FDA advisory panel on Wednesday unanimously voted in favor of FluMist, a nasal spray influenza vaccine manufactured by MedImmune,

US Health Advisers Say FluMist Is Safe  -  May 17, 2007
Sci-Tech TodayEven a limited potential for the FluMist vaccine to increase the risk of respiratory problems in the very young is a concern. Wheezing and asthma can lead

FDA Panel Votes Favorably For FluMist In Young Children  -  May 16, 2007
BioWorld Online,GAITHERSBURG, Md. - FluMist should be used in children between 1 and 5 years old, a majority of FDA advisors recommended Wednesday, supporting MedImmune

FDA Panel Supports Expanded FluMist Use  -  May 16, 2007
Washington Post,A Food and Drug Administration advisory panel unanimously agreed yesterday that MedImmune's nasal flu vaccine FluMist worked in children under age 5,

Expanded FluMist use for children supported by FDA panel  -  May 17, 2007
The News Journal,Nurse Shelly Tilley gives FluMist to Liberty Washell, 5, in Lusby, Md. Its maker is seeking approval for use in children younger than 5.

Expert Panel Recommends FluMist For Most Healthy Under 5s  -  May 17, 2007
Medical News Today,The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met yesterday to review the evidence on FluMist in the light of two questions

FDA reviewers back extension of MedImmune's FluMist  -  May 17, 2007
Pharma Times (subscription),The US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee has voted in favour of expanding FluMist to include

FluMist Use May Be Expanded  -  May 16, 2007
TheStreet.comAdvisers to the Food and Drug Administration have recommended that MedImmune's (MEDI - Cramer's Take - Stockpickr) nasal-spray flu vaccine FluMist be

FDA panel OKs MedImmune's FluMist for kids  -  May 16, 2007
CNNMoney.comFluMist earned $36.4 million in 2006, and about seven million doses have been distributed commercially between 2003 and 2007, according to the company.

MedImmune's FluMist backed for babies  -  May 16, 2007
United Press InternationalGAITHERSBURG, Md., May 16 (UPI) -- An advisory panel to the US Food and Drug Administration Wednesday backed the use of MedImmune's FluMist for children

UPDATE 2-US panel backs MedImmune's FluMist for young kids  -  May 16, 2007
ReutersO: Quote, Profile, Research FluMist influenza vaccine is beneficial for use in some younger children, a panel of medical experts told US regulators on

FDA signals approval of FluMist for kids under 5  -  May 15, 2007
Baltimore Sun,Some health experts say FluMist would be a welcome tool in combating the flu because it would help immunize children who could otherwise get the illness and

MedImmune's FluMist benefits some young kids-panel  -  May 16, 2007
ReutersO: Quote, Profile, Research FluMist influenza vaccine outweigh any possible risks for some younger children, a US advisory panel said on Wednesday.

FDA backs FluMist spray for young children  -  May 15, 2007
The News Journal,An FDA advisory panel will meet Wednesday to decide whether to recommend expanding FluMist's use to children as young as age 1 who don't have a history of

AstraZeneca mulls vaccine sale after $12.5bn MedImmune deal  -  26 Apr 2007
Business Online,A senior source within Astra-Zeneca told The Business that the company was planning “one final push� on marketing FluMist, MedImmune’s influenza vaccine.

MedImmune expected to stay in Gaithersburg  -  26 Apr 2007
Business Gazette,The company may be best known for its nasal flu vaccine, FluMist, but its biggest moneymaker, by far, is Synagis, which helps prevent respiratory infections

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion  -  Apr 23, 2007
BioWorld Online,And revenues for FluMist, a nasal-spray influenza vaccine, were $56 million. MedImmune had about $1.5 billion in cash as of Dec. 31.

AstraZeneca's Plan, Icahn's Success, S&P Record: David Wilson  -  Apr 23, 2007
BloombergThe UK's second-largest drugmaker agreed to pay $58 a share for MedImmune Inc., a US biotechnology company that produces the FluMist influenza vaccine,

FluMist maker to consider takeover  -  Apr 13, 2007
Louisville Courier-Journal,MedImmune also makes the inhaled influenza vaccine FluMist. A company spokeswoman did not immediately return a request for comment.

AstraZeneca to buy MedImmune for $15 billion  -  Apr 23, 2007
Canada.com,MedImmune's FluMist vaccine in an undated file photo. AstraZeneca Plc has agreed to buy US biotechnology company MedImmune Inc. for more than $15 billion in

AstraZeneca to Purchase MedImmune for $15.2 Billion (Update4)  -  Apr 23, 2007
BloombergThe company gets MedImmune's FluMist influenza treatment and Synagis for infant respiratory infections, as well as 45 products in development.

FluMist Maker MedImmune  -  Apr 12, 2007
Wall Street Journal (subscription),...shareholder Matrix Asset Advisors Inc. reiterated its call for selling the Gaithersburg, Md., company, which makes the nasal-spray flu vaccine FluMist,

Flu vaccine maker bought by Cheshire’s AstraZeneca  -  Apr 24, 2007
ic Liverpool,Pharmaceuticals giant AstraZeneca agreed to pay £7.6bn, subject to shareholder approval, for US vaccine maker MedImmune, which manufactures Flumist,

AstraZeneca to Buy MedImmune  -  Apr 23, 2007
Los Angeles Times,The second is a refrigerated formulation of its FluMist inhaled influenza vaccine, which will probably be launched in the coming US winter season.

AstraZeneca, struggling to develop new medicines, agrees to buy ...  -  Apr 23, 2007
International Herald Tribune,Sales of FluMist have been limited since its 2003 introduction because the treatment isn't approved for adults older than 50 or children younger than 5.

AstraZeneca to acquire MedImmune  -  Apr 23, 2007
Baltimore Sun,AstraZeneca PLC will acquire FluMist-maker MedImmune Inc. in a $15.6 billion cash deal that will advance the British pharmaceutical giant's biotechnology

AstraZeneca to Buy MedImmune for $15.6B  -  Apr 23, 2007
phillyBurbs.com,The second is a refrigerated formulation of its FluMist inhaled influenza vaccine, which will probably be launched for the winter.

Biotech MedImmune to Be Acquired by AstraZeneca  -  Apr 23, 2007
Biologic Drug Report,One of the larger independent biotech companies in the United States, MedImmune makes nasal spray flu vaccine FluMist and Synagis, a biologic drug for

AstraZeneca will buy Maryland company  -  Apr 23, 2007
Annapolis Capital,The shareholders' concerns centered on a disappointing launch of FluMist, once thought to be a blockbuster drug that fizzled when it was released four years

AstraZeneca buys US biotech firm  -  Apr 23, 2007
Guardian Unlimited,The deal gives the group the nasal spray flu vaccine FluMist and an antiviral drug for babies, Synagis. It is paying $58 a share in cash for MedImmune,

132 million flu vaccines being made for winter  -  Apr 23, 2007
Jackson Clarion Ledger,MedImmune Vaccines plans to make about 7 million doses of FluMist, a nasal mist recommended only for healthy people between 5 and 49.

AstraZeneca to buy MedImmune for $15.6 billion  -  Apr 23, 2007
Pharma Times (subscription),AstraZeneca noted that the deal also adds "two late-stage assets" to its pipeline, a refrigerated formulation of FluMist with an anticipated US launch for

AstraZeneca to Purchase MedImmune for $15.2 Billion (Update1)  -  Apr 22, 2007
BloombergMedImmune makes the FluMist influenza medicine, and the Synagis treatment for infant respiratory infections. Synagis, MedImmune's biggest product,

MedImmune FluMist Gets FDA Approval  -  Mar 29, 2007
Vaccine Rx (press release),Popularly known as FluMist, the new formulation can be stored in a refrigerated state instead of the current practice of freezing the vaccine.

AstraZeneca to buy MedImmune for $15.2bn cash  -  Apr 23, 2007
newratings.com...including billionaire investor Carl Icahn. MedImmune makes the FluMist influenza medicine, and the Synagis treatment for infant respiratory infections.

AstraZeneca to Buy MedImmune for $15.2 Billion  -  Apr 23, 2007
New York Times,Shareholders in MedImmune, which makes the flu vaccine FluMist, will receive $58 a share, a 21 percent premium over the Gaithersburg, Md. company’s closing

Astra strikes deal for US rival  -  Apr 23, 2007
Express & Echo,...respiratory tract infections in babies and children. Additionally, MedImmune also has a pipeline of 45 new products and makes the influenza vaccine FluMist.

AstraZeneca forks out $15.2bn for MedImmune  -  Apr 23, 2007
Hemscott,US-based MedImmune is focused on cancer and infectious and inflammatory diseases and will bring with it its key marketed products - Flumist for influenza,

MedImmune Gets a Deal  -  Apr 23, 2007
TheStreet.comThe transaction values MedImmune, the maker of the nasal spray flu vaccine FluMist, at $58 a share. The company had recently said it was considering its

Drug makers in $15.6B deal  -  Apr 23, 2007
Cincinnati Post,MedImmune also makes the inhaled influenza vaccine FluMist. AstraZeneca also announced a 9.5 percent increase in first-quarter net profit of $1.56 billion.

AstraZeneca closes deal on MedImmune  -  Apr 23, 2007
Pharmaceutical Business ReviewThe acquisition gives AstraZeneca two late-stage assets: the next generation follow-on to Synagis, Numax and a refrigerated formulation of FluMist with an

AstraZeneca Reports Earnings, Bids for MedImmune  -  Apr 23, 2007
Schaeffers Research,The second product is a refrigerated version of the FluMist influenza vaccine. The drug maker hopes to complete the buyout of MEDI by June.

Astra strikes deal for US rival  -  Apr 23, 2007
Ireland Online,Additionally, MedImmune also has a pipeline of 45 new products and makes the influenza vaccine FluMist. The move will significantly enhance AstraZeneca’s

AstraZeneca in $15.6bn drugs deal  -  Apr 23, 2007
BBC News,The US biotechnology business, based in Maryland, has a range of successful treatments including the respiratory drug Numax and flu vaccine FluMist.

AstraZeneca to buy MedImmune for $15.6 billion  -  Apr 23, 2007
MarketWatch...used to fight respiratory infections for babies, and a refrigerated formulation of FluMist which is designed for launch in the 2007-2008 US flu season.

AstraZeneca buys US rival for $15.2bn  -  Apr 23, 2007
Telegraph.co.uk,MedImmune makes the FluMist influenza medicine, and the Synagis treatment for infant respiratory infections. Synagis, MedImmune’s biggest product,

AstraZeneca Buys MedImmune For $15.6 Billion  -  Apr 23, 2007
Playfuls.com,...buy acquiring MedImmune’s FluMist influenza treatment, Synagis for infant respiratory infections, and Ethyol for reducing chemotherapy side effects.

Health Digest  -  Apr 21, 2007
Nashua Telegraph (subscription),Caveats: The study was funded by MedImmune, which makes FluMist; data analysis was done by its employees, four of whom were among the eight primary authors.

AstraZeneca Near Deal to Buy MedImmune - WSJ  -  Apr 22, 2007
Reuters.uk,MedImmune, one of the larger independent biotech firms in the United States, is best known as the maker of the nasal spray flu vaccine FluMist,

St. Mary's County's School Vaccination Program Has Highest ...  -  Apr 22, 2007
Southern Maryland Online,The Department of Health and Mental Hygiene (DHMH) began the FluMist campaign in October, initiating a project that would take 5 months and immunize over

More flu vaccine than we need  -  Apr 20, 2007
Marketplace,The company says they'll be better than expected even though only 3 million doses of its inhaled flu vaccine FluMist were sold.

Research Results on FluMist(R) Presented at National Association ...  -  Mar 23, 2007
Drug Newswire (press release),A third study of nearly 8500 children six months to 5 years of age found that children vaccinated with FluMist experienced 55 percent fewer cases of

Medimmune to present FluMist research results at conference  -  Mar 21, 2007
MarketWatch...said researchers will present data from three studies involving its nasal-spray flu vaccine FluMist at a pediatric nurse practicioners' conference in Lake

Flumist Found To Be More Effective Than Shot  -  Mar 6, 2007
WTVF,A Vanderbilt researcher found the nasal flu spray Flumist may be twice as effective in young children. A recent study showed that 55 percent fewer children,

MedImmune Leases Human Genome Sciences Facility to Expand Cell ...  -  Mar 16, 2007
PR Newswire (press release),FluMist is currently indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents

Revised Labeling Approved for Flumadine  -  Mar 20, 2007
Facts and Comparisons,Because of the potential for interference between Flumadine and FluMist (influenza virus vaccine live, intranasal), it is advised that FluMist not be

MedImmune "overweight," estimates reduced  -  Mar 19, 2007
newratings.comIn a research note published this morning, the analyst mentions that the 1Q07 sales estimate for Flumist has been reduced from $10.7 million to $2.1 million

MedImmune rebuffs critics, advances product line  -  Feb 28, 2007
Business Gazette,A new study of 8475 children ages six to 59 months showed that MedImmune’s FluMist nasal vaccine gives more effective protection from influenza than

MedImmune Leases New Facility to Enhance Flu Vaccine Program  -  Mar 16, 2007
Genetic Engineering News (press release),MedImmune currently develops, manufactures, and markets FluMist®, a live, attenuated, needle-free seasonal influenza vaccine. The company is also working

Don't flu around  -  Mar 2, 2007
Keizertimes,For those who cannot abide shots there is the new FluMist nasal spray. FluMist is supposed to be at least as safe and effective as the injected vaccine.

Flu mist found more effective for youngsters  -  Mar 6, 2007
Ashland City Times,The nasal spray dubbed, FluMist, is not currently approved for use in children under age 5. Edwards said the success of the study could lead to approval for

Late-season flu cases spiking in Oregon  -  Mar 1, 2007
kgw.com (subscription),In addition to injectable vaccine, a prescription nasal spray called FluMist is available. Flu symptoms include fever, dry cough, muscle aches, headaches,

US Stock-Index Futures Decline; Oracle, Citigroup Retreat  -  Mar 20, 2007
BloombergMedImmune Inc., maker of the FluMist vaccine, retreated 34 cents to $32.70 after Bear Stearns lowered its recommendation to ``peer perform'' from

Vanderbilt Children’s Hospital study proves nasal spray flu ...  -  Mar 6, 2007
Vanderbilt University News,The nasal spray flu vaccine, licensed for children over 5 years of age as Flumist, has been available for a couple of years now. However, the vaccine has

Culture May Stop The Slim Down in Overweight Black Women  -  Feb 28, 2007
BET,15, 2007 – Children will probably be cheering when they hear that the nasal spray flu vaccine FluMist i s much more effective for children than a flu shot.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional